Business context and reporting period
The supplied filing is Cyclacel Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2021. This does not match the request metadata naming Bio Green Med Solution, Inc.; confirm the intended issuer before relying on this summary. Cyclacel is a clinical-stage biopharmaceutical company developing cancer drug candidates, including fadraciclib, CYC140 and sapacitabine.
Financial results and liquidity
Amounts below are in millions of dollars unless noted. The company reported no revenue in the three- or nine-month periods in either 2021 or 2020; it said no revenue is expected in the foreseeable future absent active collaboration, licensing or clinical supply agreements.
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Research and development expense | $4.217 | $1.075 | $10.884 | $3.344 |
| General and administrative expense | $1.781 | $1.497 | $5.520 | $4.124 |
| Operating loss | $(5.998) | $(2.572) | $(16.404) | $(7.468) |
| Net loss | $(4.987) | $(2.256) | $(13.593) | $(5.641) |
| Net loss per common share | $(0.54) | $(0.47) | $(1.60) | $(1.81) |
Q3 2021 income tax benefit was $0.998 million, primarily from UK research and development tax credits; total other income was $0.013 million. No operating margin is meaningful given the absence of revenue and ongoing losses.
- At September 30, 2021, cash and cash equivalents were $40.219 million, up from $33.406 million at December 31, 2020. Current assets were $43.375 million and current liabilities $3.591 million, yielding working capital of $39.784 million.
- Total liabilities were $3.635 million, including a $0.044 million lease liability. The filing says the company is not reliant on institutional credit financing; it reports no conventional borrowing balance.
- For the first nine months of 2021, operating cash use was $13.991 million, investing cash use $0.025 million, and financing cash inflow $20.850 million. Financing included $13.5 million from a March stock offering, $4.5 million from warrant exercises and $3.0 million from at-the-market share sales, offset by preferred dividends.
- Accumulated deficit was $379.664 million. Common shares outstanding increased from 6,246,896 at year-end 2020 to 9,797,735 at September 30, 2021; the filing reports 9,975,135 outstanding as of November 10, 2021.
Material changes and unusual items
Compared with the prior-year periods, operating expenses and losses rose substantially, mainly as clinical development advanced. Nine-month research and development expense increased 225%, led by fadraciclib and CYC140; management attributed increases to clinical supply manufacturing, trial-site openings and preclinical work. General and administrative expense increased 34% for the nine months, including a roughly $0.4 million reverse premium related to assigning the Dundee lease and higher legal, professional and recruitment costs.
The Dundee, Scotland operating lease was assigned in May 2021, leaving no further obligations for that facility. A remaining $0.2 million installment of the approximately $0.4 million reverse premium was payable in May 2022. The company received $0.144 million of royalty-related other income in the first nine months of 2021, versus $0.891 million in the prior-year period; the timing and amount of future receipts are uncertain.
Outlook, risks and contingencies
- Management estimated that September 30 cash would fund operating expenses and capital requirements through early 2023. It stated that additional capital will be needed beyond then and that current resources are insufficient to complete development and commercialization of any candidate.
- Management expected 2021 research and development spending to exceed 2020 levels as clinical programs progress, and general and administrative spending to increase by approximately 20%, partly due to the lease assignment and professional and recruitment costs.
- Future financing may require equity, debt or strategic collaborations. If funding is unavailable on acceptable terms, Cyclacel may delay, reduce or end trials or research programs, change its operating plan, or partner programs earlier than planned, potentially reducing their economic value.
- COVID-19 could affect financing access and the timing of clinical studies; the impact was described as uncertain. The filing reported no material changes to previously disclosed risk factors and no legal proceedings.
Important facts for investors to verify
- Confirm issuer identity: the filing is for Cyclacel Pharmaceuticals, Inc., not the company named in the request metadata.
- Verify cash runway assumptions and the timing and terms of any future financing, including subsequent at-the-market share sales.
- Track clinical progress, trial costs and whether the fadraciclib and CYC140 spending increases lead to planned development milestones.
- Review potential dilution from outstanding warrants, preferred stock, options and the $50 million at-the-market sales agreement.
- Assess the collectability and timing of UK research and development tax credits and any royalty receipts, which are uncertain and affect liquidity.